CSL Limited announced Deborah Waterhouse as its new CEO and Managing Director effective February 1, 2027. Waterhouse brings over 25 years of global pharma experience, currently leading ViiV Healthcare and serving as President of GSK Global Health. The board praised her proven ability to grow complex businesses and renew pipelines, aiming to continue CSL's commercial momentum and simplify operations. She will be based in the UK but will spend significant time in CSL's key markets, succeeding interim CEO Gordon Naylor.
CSL's appointment of Deborah Waterhouse as CEO and Managing Director provides context for health sector market activity on Pluang. For readers following health stocks, here is Pluang's market snapshot as of Oct 21, 2026 14:21 WIB: Out of 150 priced US health-sector stocks, 118 rose and 30 fell today. Relay Therapeutics (RLAY) gained 8.54% to USD 18.55 with a typical hold time of 11 days, Spyre Therapeutics (SYRE) rose 8.30% to USD 91.75 with a near-even Pluang order split and a 2-day hold time, while Nuvation Bio (NUVB) increased 8.04% to USD 4.84 with a 12-day typical hold time.
A webinar titled "Ready for AI?" scheduled for October 29, 2026, will discuss how artificial intelligence is reshaping public relations by changing how information is found, evaluated, and shared. Experts will share insights on maintaining message vi...
17a-4 LLC introduced DataParser Hub, an API that enables clients to integrate proprietary messaging and collaboration data into Microsoft 365 Purview and Copilot. This solution supports over 30 data types from platforms like Slack, Zoom, and Webex, a...
IBA has treated the first patient in the C-FLASH-01 clinical trial, the first human study testing ConformalFLASH® proton therapy. This trial, conducted at Penn Medicine with FDA approval, explores the feasibility of using ultra-high dose rate proton ...
IBA has treated the first patient in the C-FLASH-01 clinical trial, testing its ConformalFLASH® proton therapy for head and neck cancer re-irradiation. This trial, led by Penn Medicine and approved by the FDA, explores ultra-high dose rate proton the...
WISeQey Corp. completed its redomiciliation and began trading on Nasdaq and the SIX Swiss Exchange, marking a new phase focused on integrating its quantum cybersecurity, digital identity, and space IoT technologies. Its subsidiary WISeSat.Space also ...
